Table 1. Clinicopathological characteristics of the validation and prospective cohorts.
| Validation cohort | |||
|---|---|---|---|
| Lung cancer | CMMA | Colon cancer | |
| Number of patients | 40 | 22 | 19 |
| FFPE/Cytology (%) | 70/30 | 100/0 | 100/0 |
| Number of hot spot mutation calls (mut/no mutation) | 8/32 | 9/13 | 12/18 |
| KRAS | - | - | 10/8 |
| NRAS | - | 0/1 | 1/5 |
| BRAF | - | 9/12 | 1/5 |
| EGFR | 8/32 | - | - |
| Prospective cohort of lung cancer cases (n=533) | ||||
|---|---|---|---|---|
| ACB | SqCCB | NSCLC-NOSB | OtherB | |
| Number of patients (%) | 348 (65%) | 90 (17%) | 80 (15%) | 15 (3%) |
| FFPE/Cytology (%) | 79/21 | 84/16 | 47/53 | 60/40 |
| Median age (years±sd) | 69±9 | 72±8.3 | 70±8.5 | 68±7.6 |
| Sex (female/male %) | 53/47 | 38/62 | 51/49 | 60/40 |
| Early stage cancer (%) | 12.5% | 7.8% | 0% | 20% |
| Clinical ALK analysis (ntot=491) | 324 | 86 | 68 | 13 |
| ALK FISH-positive (n) | 10 | 0 | 4 | 0 |
| ALK IHC-positive (n) | 2 | 2 | 1 | 1 |
| NanoString analyzed casesC (%) | 68 (50%) | 54 (40%) | 8 (6%) | 5 (4%) |
A: CMM: cutaneous malignant melanoma.
B: AC: adenocarcinoma, SqCC: squamous cell carcinoma, NSCLC-NOS: non-small cell lung cancer not otherwise specified, Other: including adenosquamous, large cell carcinoma, large cell neuroendocrine carcinoma, sarcomatoids.
C: Only cases that were KRAS/EGFR/BRAF mutation negative, from FFPE tissue, and with successful NanoString hybridizations are listed.